Published in Childs Nerv Syst on August 29, 2006
Soft tissue sarcomas and central nervous system tumors in children with neurofibromatosis type 1. Childs Nerv Syst (2011) 0.79
Lobar haemorrhagic mass in a young girl with neurofibromatosis type 1. BMJ Case Rep (2013) 0.75
Management of glioblastoma in an NF1 patient with moyamoya syndrome: a case report. Childs Nerv Syst (2012) 0.75
Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet (2000) 3.98
An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet (1993) 2.79
Malignancy in neurofibromatosis type 1. Oncologist (2000) 2.78
Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol (2002) 2.65
Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr (1994) 2.63
Outcomes of systematic screening for optic pathway tumors in children with Neurofibromatosis Type 1. Am J Med Genet A (2004) 1.90
Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J Neurosci (2005) 1.33
Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res (2005) 1.30
Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet (1999) 1.29
Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene. Anticancer Res (2005) 1.08
Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1. Neurology (2003) 1.05
Neurofibromatosis bright objects in children with neurofibromatosis type 1: a proliferative potential? Pediatrics (1999) 0.96
Health supervision for children with neurofibromatosis. American Academy of Pediatrics Committee on Genetics. Pediatrics (1995) 0.89
Pediatric high-grade gliomas. Cancer J (2003) 0.86
Central nervous system imaging in reevaluation of patients with neurofibromatosis type 1. Childs Nerv Syst (1993) 0.82
Unusual clustering of brain tumours in a family with NF1 and variable expression of cutaneous features. J Med Genet (1999) 0.81
Imaging considerations of central nervous system manifestations in pediatric patients with neurofibromatosis type 1. Pediatr Radiol (1991) 0.75
High-intensity lesion on T1-weighted MR images in neurofibromatosis type 1: a case of premalignant lesion. Acta Neurochir (Wien) (1997) 0.75
International network of cancer genome projects. Nature (2010) 20.35
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol (2009) 7.73
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol (2012) 6.20
Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood (2004) 6.02
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Long-term survival with glioblastoma multiforme. Brain (2007) 4.51
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol (2009) 4.32
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature (2012) 4.04
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med (2012) 3.67
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (2011) 3.66
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol (2009) 3.65
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol (2009) 3.32
Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol (2005) 3.29
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Histological classification and molecular genetics of meningiomas. Lancet Neurol (2006) 3.19
Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res (2007) 3.05
Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol (2009) 3.01
Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res (2008) 2.84
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol (2010) 2.71
Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol (2009) 2.67
Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics (2003) 2.66
Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study. Lancet Oncol (2013) 2.64
NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in d-2-hydroxyglutaric aciduria. Eur J Neurosci (2002) 2.54
A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain (2010) 2.49
POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res (2003) 2.45
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol (2003) 2.38
O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain (2005) 2.37
Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. J Clin Oncol (2005) 2.36
EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell (2013) 2.28
Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol (2012) 2.17
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol (2007) 2.11
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology (2013) 1.98
Fanconi syndrome caused by antiepileptic therapy with valproic Acid. Epilepsia (2004) 1.87
Fabry disease-often seen, rarely diagnosed. Dtsch Arztebl Int (2009) 1.85
Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol (2005) 1.83
Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis. Haematologica (2005) 1.83
Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol (2008) 1.74
Mitochondrial complex I deficiency: from organelle dysfunction to clinical disease. Brain (2009) 1.71
An immunodeficiency disease with RAG mutations and granulomas. N Engl J Med (2008) 1.71
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol (2012) 1.68
Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer (2007) 1.67
Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol (2010) 1.65
Early clinical experiences with the new influenza A (H1N1/09). Dtsch Arztebl Int (2009) 1.65
Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol (2010) 1.65
Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res (2005) 1.63
Pten signaling in gliomas. Neuro Oncol (2002) 1.62
Physical exercise-induced hypoglycemia caused by failed silencing of monocarboxylate transporter 1 in pancreatic beta cells. Am J Hum Genet (2007) 1.62
Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res (2009) 1.61
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer (2011) 1.61
Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol (2003) 1.57
Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol (2004) 1.55
Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol (2013) 1.50
Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer (2004) 1.50
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer (2005) 1.48
Delayed diagnosis and complications of Fanconi anaemia at advanced age--a paradigm. Br J Haematol (2006) 1.48
Pseudotumor cerebri as an important differential diagnosis of papilledema in children. Brain Dev (2005) 1.46
Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol (2009) 1.46
The nuclear receptor tailless induces long-term neural stem cell expansion and brain tumor initiation. Genes Dev (2010) 1.45
Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urology (2002) 1.44
ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma. BMC Cancer (2009) 1.44
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol (2006) 1.43
Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol (2014) 1.42
Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis. Dev Med Child Neurol (2009) 1.42
Molecular pathogenesis of meningiomas. J Neurooncol (2004) 1.42
Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol (2007) 1.42
Genomic and expression profiling of human spermatocytic seminomas: primary spermatocyte as tumorigenic precursor and DMRT1 as candidate chromosome 9 gene. Cancer Res (2006) 1.41
Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet (2003) 1.41
Troglitazone-mediated sensitization to TRAIL-induced apoptosis is regulated by proteasome-dependent degradation of FLIP and ERK1/2-dependent phosphorylation of BAD. Cancer Biol Ther (2008) 1.41
Baby-walkers: an avoidable source of hazard. Lancet (2008) 1.41
Crossed cerebellar diaschisis after status epilepticus in a young child. Neuropediatrics (2012) 1.40
Molecular diagnostics of gliomas: state of the art. Acta Neuropathol (2010) 1.40
Unusual radiological presentation of tuberous sclerosis complex with leptomeningeal angiomatosis associated with a hypomorphic mutation in the TSC2 gene. J Child Neurol (2009) 1.39
Neonatal screening for very long-chain acyl-coA dehydrogenase deficiency: enzymatic and molecular evaluation of neonates with elevated C14:1-carnitine levels. Pediatrics (2006) 1.38
Genotype and protein expression after bone marrow transplantation for adrenoleukodystrophy. Arch Neurol (2007) 1.38
Hunter disease before and during enzyme replacement therapy. Pediatr Neurol (2011) 1.38
Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol (2013) 1.37
Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer (2005) 1.36
Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol (2015) 1.35
Physical exercise-induced hyperinsulinemic hypoglycemia is an autosomal-dominant trait characterized by abnormal pyruvate-induced insulin release. Diabetes (2003) 1.33
Pitfalls of neonatal screening for very-long-chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry. J Pediatr (2006) 1.33
Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer (2008) 1.33
A guide to diagnosis and treatment of Leigh syndrome. J Neurol Neurosurg Psychiatry (2013) 1.31
Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res (2004) 1.31
Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. Int J Cancer (2010) 1.31